KM Research Hub
← 返回论文库
已完成 入排:排除 图源:可得 入排置信度 0.98

Finerenone, chronic obstructive pulmonary disease, and heart failure with mildly reduced or preserved ejection fraction: A prespecified analysis of the FINEARTS-HF trial.

Jawad H Butt, Pardeep S Jhund, Alasdair D Henderson, Brian L Claggett, Akshay S Desai, Carolyn S P Lam, Katharina Mueller, Markus F Scheerer, Prabhakar Viswanathan, Michele Senni, Sanjiv J Shah, Adriaan A Voors, Faiez Zannad, Bertram Pitt, Muthiah Vaduganathan, Scott D Solomon, John J V McMurray

Eur J Heart Fail 27(8) 1444-1458

PMID40222820
PMCIDPMC12482838
DOI10.1002/ejhf.3661
发表日期2025-04-13
入排依据:未发现恶性肿瘤人群证据。
摘要

摘要

AIMS: Chronic obstructive pulmonary disease (COPD) is associated with worse outcomes in heart failure (HF) with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF). A post hoc analysis of TOPCAT suggested that the effectiveness of the steroidal mineralocorticoid receptor antagonist (MRA), spironolactone, may be modified by pulmonary disease, with a greater benefit in patients with COPD/asthma. We examined the effects of the non-steroidal MRA, finerenone, compared to placebo, according to COPD status in a prespecified analysis of FINEARTS-HF. METHODS AND RESULTS: A history of COPD was investigator-reported. The primary outcome was the composite of cardiovascular death and total worsening HF events. Of the 6001 patients randomized in FINEARTS-HF, 773 patients (12.9%) had COPD. Compared to patients without COPD, those with COPD had more adverse clinical features, including worse New York Heart Association class and Kansas City Cardiomyopathy Questionnaire (KCCQ) scores, more prior HF hospitalization, atrial fibrillation/flutter, obesity, peripheral artery disease, and hypertension, as well as elevated high-sensitivity troponin T levels. Patients with COPD had a higher risk of the primary endpoint (adjusted rate ratio [RR] 1.44, 95% confidence interval [CI] 1.21-1.71). The benefit of finerenone on the primary outcome was consistent irrespective of COPD status (no COPD: RR 0.84 [95% CI 0.73-0.97]; COPD: 0.84 [95% CI 0.61-1.16]; pinteraction = 0.93). Consistent effects were also observed for all secondary outcomes. Finerenone improved KCCQ total symptom score from baseline to 12 months to a similar extent in patients with and without COPD (pinteraction = 0.46). CONCLUSION: In patients with HFmrEF/HFpEF, the beneficial effects of finerenone on clinical events and symptoms were consistent, regardless of COPD status. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov ID NCT04435626.

KM 提取结果

1 个 Figure · 1 个 KM 面板

进入结果中心
KM Figure1 个面板

Figure 4

Figure 4 Cardiovascular death and total worsening heart failure (HF) events in patients randomized to finerenone or placebo according to a history of chronic obstructive pulmonary disease (COPD).

Figure_4

Cardiovascular death and total worsening HF events

Figure 4 · Panel Figure_4

complete 待 EXE 对齐 预期 4 条 已提取 4 条

Panel Figure_4 是同一 Figure 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 3:off origin start曲线 4:off origin start
查看结果
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1 Mean baseline Kansas City Cardiomyopathy Questionnaire (KCCQ) scores associated with major comorbidities. Anaemia is defined as a haemoglobin level < 130 g/L for men and < 120 g/L for women; CKD is defined as an estimated glomerular filtration rate < 60 ml/min/1.73 m 2 ; obesity is defined as a body mass index >30 kg/m 2 . AF/AFL, atrial fibrillation/flutter; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; CSS, clinical summary score; DM2, type 2 diabetes; HTN, hypertension; OSS, overall summary score; TSS, total symptom score.
非 KM Figure
Figure 2Figure 2 Outcomes associated with major comorbidities. ( A ) Cardiovascular death and total worsening heart failure events. ( B ) All‐cause death. Anaemia is defined as a haemoglobin level <130 g/L for men and <120 g/L for women; chronic kidney disease is defined as an estimated glomerular filtration rate <60 ml/min/1.73 m 2 ; obesity is defined as a body mass index >30 kg/m 2 . Rate/hazard ratio >1: a history of the comorbidity of interest is associated with a higher risk compared with no history. Rate/hazard ratio <1: a history of the comorbidity of interest is associated with a lower risk compared with no history. One model was created for each comorbidity, and models were stratified by geographic region and left ventricular ejection fraction stratification and adjusted for treatment assignment, age, sex, New York Heart Associational functional class, and log of N‐terminal pro‐B‐type natriuretic peptide. CI, confidence interval; COPD, chronic obstructive pulmonary disease.
非 KM Figure
Figure 3Figure 3 Adjudicated causes of death according to a history of chronic obstructive pulmonary disease (COPD). CV, cardiovascular; MI, myocardial infarction.
非 KM Figure